Atossa plans stapled CVR tied to rare pediatric disease review voucherSep 29Regulatory milestoneAtossa Therapeutics, Inc.
Atossa reports Q2 2026 results, completes enrollment in EVANGELINE trialAug 7Quarterly updateAtossa Therapeutics, Inc.endoxifen
Sign inSign in